Akimichi Morita, MD, PhD is an expert in Dermatology at Nagoya City University (Japan). As of October 2026, ScienceLeadR ranks Akimichi Morita in the top 1% of experts worldwide for Psoriasis and Skin Diseases, Papulosquamous. Akimichi Morita has authored 609 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 3 of them ongoing. SLR score: 2,849 (community average: 125). How the SLR is computed.

LeadR Profile

Akimichi Morita, MD, PhD Nagoya City University Japan
2 849 ScienceLeadR Reputation 2849
Network Map

Dermatology

Subspecialties: Public Health - Immunology - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Professor Akimichi Morita graduated from Nagoya City University and received his MD in 1989. He later received his Ph.D. in basic immunology from Aichi Cancer Center in Nagoya. As a Humboldt Foundation Fellow, he studied photobiology and photoimmunology at Düsseldorf University in Düsseldorf, Germany, and underwent further training at the University of Texas Southwestern Medical Center in Dallas, TX, USA. Since then, he has introduced numerous standard phototherapies to Japan. He was appointed Professor and Chairman of the Department of Geriatric and Environmental Dermatology at Nagoya City University Graduate School of Medical Sciences in 2003 and currently holds the position of Vice Director of Nagoya City University Hospital. Professor Morita’s main research interests are photobiology, phototherapy, cutaneous immunology, skin aging, cutaneous T-cell lymphoma, and psoriasis.


Professor Morita holds the title of President at the Japanese Society for Psoriasis Research (2022-) and is a board of directors for the International Council of Psoriasis (IPC, 2023-). He was the President of the Japanese Society for Photomedicine and Photobiology (2018-2022) and the President of the Japanese Society for Investigative Dermatology (JSID)(2017-2020). He is an editorial board member of several prestigious medical journals and currently serves as Editor-in-Chief of Experimental Dermatology. He also served as Editor-in-Chief of the journal Photodermatology, Photomedicine & Photoimmunology (2018-2021) and Editor-in-Chief of the Journal of Dermatological Science(2008-2013). In addition, he has published over 300 articles in peer-reviewed journals (H-index: 56) and has written 26 books or book chapters.


Organizations

Career arc: 1989 - 2026

Source: PubMed

Nagoya City University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 609

Citations

Citations: 12 441 1st author: 55 Last author: 269 Unique author: 13


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Beyond the league table: Translating scalp clearance into patient-centred psoriasis care.
PMID 42926335 — sexually transmitted diseases, translating, skin diseases, psoriasis
J Eur Acad Dermatol Venereol20260
Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study.
PMID 42791206 — quality of life, ustekinumab, syphilis, safety, therapeutics, psoriasis, dermatology
Br J Dermatol20260
Topical Cycling and Systemic Eligibility in Patients With Psoriasis in Japan.
PMID 42499214 — treatment switching, therapeutics, psoriasis, dermatology
J Dermatol20260
Umbilical Cord-Derived Therapies for Wound Healing: A Scoping Review of Clinical and Translational Evidence.
PMID 42702852 — skin, safety, multiple chronic conditions, stem cells, skin diseases, exosomes, research, therapeutics, umbilical cord
Exp Dermatol20260
Real-world safety profile of spesolimab in generalised pustular psoriasis: expanded access programmes in Japan, China and Argentina.
PMID 42701320 — syphilis, safety, psoriasis, dermatology
Br J Dermatol20260

Clinical Studies 19

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 3 9
Phase 2 7
N/A 1
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 16
Recruiting 3

By type:

Interventional 18
Observational 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 1
multicentricup10 16

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058 — arthritis, psoriatic, safety, pharmaceutical preparations, arthritis, tablets, drug therapy, therapeutics
Phase 3Recruiting2026
A Long Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802 — safety, pharmaceutical preparations, drug therapy, aged, therapeutics, psoriasis, child, pharmacokinetics
Phase 3Recruiting2025
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
NCT07108283 — skin, safety, pharmaceutical preparations, vitiligo, drug therapy, capsules, immune system, therapeutics
Phase 2Recruiting2025

LeadR Networks

Main global connection map